Tag: Quality-adjusted life year

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Quality-adjusted life year

Count the cost of disability caused by COVID-19

Added to Collection on: 2021-05-26 15:20:34

Tags for this article:

Articles
Health
Health economics
Global health
Public health
Occupational safety and health
Health informatics
Disability-adjusted life year
Disease burden
Quality-adjusted life year
Institute for Health Metrics and Evaluation
COVID-19 pandemic
United States

Click the tags to see associated articles and topics

View Article Details
Value Blueprints Research Brief Explores Patient-Driven Value Element Framework to Identify ...

Added to Collection on: 2021-06-03 17:15:00

Tags for this article:

Health care quality
Health
Quality-adjusted life year
Articles

Click the tags to see associated articles and topics

View Article Details
Coronapod: counting the cost of long COVID

Added to Collection on: 2021-06-11 22:30:00

Tags for this article:

Articles
Health economics
Health
Global health
Health care quality
Disability-adjusted life year
World Health Organization
Quality-adjusted life year
Podcast

Click the tags to see associated articles and topics

View Article Details
Hart: Lower Drug Cost Act would cost NJ more than 70K jobs

Added to Collection on: 2021-06-14 11:03:45

Tags for this article:

Health
Pharmaceutical industry
Healthcare reform in the United States
Drug pricing
Health economics
Elijah Cummings Lower Drug Costs Now Act
Medication costs
Medicare
Medication
Quality-adjusted life year

Click the tags to see associated articles and topics

View Article Details
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Added to Collection on: 2021-07-23 19:41:15

Tags for this article:

Health
Health care quality
Health economics
Orphan drugs
Pharmacy
Alexion Pharmaceuticals
AstraZeneca
Eculizumab
Institute for Clinical and Economic Review
Quality-adjusted life year
Myasthenia gravis
Oxford–AstraZeneca COVID-19 vaccine
Soliris

Click the tags to see associated articles and topics

View Article Details
Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow ...

Added to Collection on: 2021-08-12 00:56:15

Tags for this article:

Health
Organic compounds
Health care quality
Health economics
Antiviral drugs
COVID-19 drug development
Remdesivir
Quality-adjusted life year
Incremental cost-effectiveness ratio

Click the tags to see associated articles and topics

View Article Details
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits -report - Yahoo News

Added to Collection on: 2022-02-03 19:10:32

Tags for this article:

Health
COVID-19 drug development
Health care quality
Health economics
Antiviral drugs
Costs
Institute for Clinical and Economic Review
Sotrovimab
Molnupiravir
Quality-adjusted life year
SARS-CoV-2 Omicron variant
Merck & Co.

Click the tags to see associated articles and topics

View Article Details
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits -report | Reuters

Added to Collection on: 2022-02-04 09:37:13

Tags for this article:

Health
COVID-19 drug development
Health economics
Antiviral drugs
Health care quality
Costs
Sotrovimab
Institute for Clinical and Economic Review
Molnupiravir
SARS-CoV-2 Omicron variant
Quality-adjusted life year
Merck & Co.

Click the tags to see associated articles and topics

View Article Details
Industry-funded studies more likely to find new treatments cost effective - Brighter World

Added to Collection on: 2022-06-23 16:06:10

Tags for this article:

Health
Health economics
Health care quality
Pharmacy
Quality-adjusted life year
Pharmaceutical industry
Cost-effectiveness analysis
Feng Xie

Click the tags to see associated articles and topics

View Article Details
CAR-T Therapies Cost Prohibitive for Diffuse Large B-Cell Lymphoma Treatment

Added to Collection on: 2022-12-21 01:46:41

Tags for this article:

Health
Articles
Health economics
Healthcare quality
Costs
RTT
Cancer treatments
Incremental cost-effectiveness ratio
Chimeric antigen receptor T cell
Quality-adjusted life year
Doxorubicin
Axicabtagene ciloleucel
United States

Click the tags to see associated articles and topics

View Article Details